Table 2.
Tumor characteristics and treatment
| All HCC (n=2237) |
Non-cirrhotic HCC (n = 290) |
Cirrhotic HCC(n = 1947) |
p value | |
|---|---|---|---|---|
| Histologic confirmation of HCC, n(%) | 1395 (62.4) | 280 (96.6) | 1115 (57.3) | < 0.001 |
| Largest tumor diameter, cm, median (IQR) | 4 (2.6, 7) | 7.8 (5, 11.5) | 3.7 (2.5, 6.1) | < 0.001 |
| Largest tumor size > 5 cm, n(%) | 868 (38.8) | 215 (74.1) | 653 (33.5) | < 0.001 |
| Major vascular invasion, n(%) | 340 (15.2) | 21 (7.2) | 319 (16.4) | < 0.001 |
| Metastasis, n(%) | 182 (8.1) | 28 (9.7) | 154 (7.9) | 0.310 |
| BCLC stage, n(%) | < 0.001 | |||
| Very early | 150 (6.7) | 11 (3.8) | 139 (7.1) | |
| Early | 674 (30.1) | 49 (16.9) | 625 (32.1) | |
| Intermediate | 749 (33.5) | 172 (59.3) | 577 (29.6) | |
| Advanced | 403 (18.0) | 54 (18.6) | 349 (17.9) | |
| Terminal | 261 (11.7) | 4 (1.4) | 257 (13.2) | |
| Tumor within Milan criteria, n(%) | 952 (42.6) | 60 (20.7) | 892 (45.8) | < 0.001 |
| Received transplant, n(%) | 520 (23.3) | 7 (2.4) | 513 (26.4) | < 0.001 |
| Initial treatment received, n(%) | ||||
| Resection | 261 (11.7) | 151 (52.1) | 110 (5.7) | < 0.001 |
| Curative locoregional therapya | 171 (7.6) | 12 (4.1) | 159 (8.2) | 0.013 |
| Liver transplantation | 212 (9.5) | 2 (0.7) | 210 (10.8) | < 0.001 |
| Bridging therapy and transplantation | 292 (13.1) | 3 (1.0) | 289 (14.8) | < 0.001 |
| Palliative locoregional therapyb | 578 (25.8) | 43 (14.8) | 535 (27.5) | < 0.001 |
| Systemic therapy | 161 (7.2) | 17 (5.9) | 144 (7.4) | 0.395 |
| Other | 7 (0.3) | 1 (0.3) | 6 (0.3) | 1.000 |
| Supportive care | 428 (19.1) | 57 (19.7) | 371 (19.1) | 0.808 |
| Unknown | 127 (5.7) | 4 (1.4) | 123 (6.3) | 0.001 |
a
Radiofrequency ablation, microwave ablation, direct ethanol injection
b
Trans arterial chemoembolization, Y90 radioembolization, stereotactic body radiation therapy